La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Cutia Therapeutics Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Lele Zhang

Amministratore delegato

CN¥50.6m

Compenso totale

Percentuale dello stipendio del CEO	5.6%
Mandato del CEO	4.9yrs
Proprietà del CEO	n/a
Durata media del management	2.3yrs
Durata media del Consiglio di amministrazione	4yrs

Aggiornamenti recenti sulla gestione

Recent updates

A Look At The Intrinsic Value Of Cutia Therapeutics (HKG:2487)

Jun 03

Analysts Are Betting On Cutia Therapeutics (HKG:2487) With A Big Upgrade This Week

Apr 08

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Lele Zhang rispetto agli utili di Cutia Therapeutics?
Data	Compenso totale	Stipendio	Guadagni aziendali
Dec 31 2023	CN¥51m	CN¥3m	-CN¥2b
Sep 30 2023	n/a	n/a	-CN¥2b
Jun 30 2023	n/a	n/a	-CN¥2b
Mar 31 2023	n/a	n/a	-CN¥1b
Dec 31 2022	CN¥21m	CN¥4m	-CN¥556m
Dec 31 2021	CN¥27m	CN¥3m	-CN¥320m

Compensazione vs Mercato: La retribuzione totale di Lele ($USD 7.09M ) è superiore alla media delle aziende di dimensioni simili nel mercato Hong Kong ($USD 408.00K ).

Compensazione vs guadagni: La retribuzione di Lele è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Lele Zhang (47 yo)

4.9yrs

Mandato

CN¥50,602,000

Compensazione

Ms. Lele Zhang is founder of Cutia Therapeutics. She serves as Director of Cutia Therapeutics since May 12, 2020 and serves as ts Executive Director since November 15, 2022. Ms. Zhang has been CEO of Cutia...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Lele Zhang	Founder	4.9yrs	CN¥50.60m	Nessun dato
Yuqing Huang	CFO & Executive Director	3.3yrs	CN¥16.72m	Nessun dato
Qi Zhu	Chief Medical Officer	4.9yrs	Nessun dato	Nessun dato
Lei Lei	Senior Vice President of Research & Development Department	1.9yrs	Nessun dato	Nessun dato
Chunna Zhang	Senior Vice President of Regulatory Affairs Department	1.9yrs	Nessun dato	Nessun dato
Jingxin Xu	Senior Vice President of Manufacturing & Quality Control Department	2.6yrs	Nessun dato	Nessun dato
Jiaru Wu	Senior Vice President of Finance & Integrated Management Department	1.8yrs	Nessun dato	Nessun dato
Sze Ting Chan	Company Secretary	1.8yrs	Nessun dato	Nessun dato

2.3yrs

Durata media

43.5yo

Età media

Gestione esperta: Il team dirigenziale di 2487 è considerato esperto (durata media dell'incarico 2.3 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Lele Zhang	Founder	4.3yrs	CN¥50.60m	Nessun dato
Yuqing Huang	CFO & Executive Director	1.8yrs	CN¥16.72m	Nessun dato
Lian Yong Chen	Non-Executive Chairman of the Board	5yrs	Nessun dato	Nessun dato
Ming Kit Chung	Independent Non-Executive Director	1.3yrs	CN¥201.00k	Nessun dato
Yunxia Yang	Non-Executive Director	4yrs	Nessun dato	Nessun dato
Qin Xie	Non-Executive Director	5yrs	Nessun dato	Nessun dato
Xiao Huang	Non-Executive Director	4yrs	Nessun dato	Nessun dato
Tak Yan Tao	Independent Non-Executive Director	1.3yrs	CN¥201.00k	Nessun dato
Xiaoxiang Ye	Independent Non-Executive Director	1.3yrs	CN¥201.00k	Nessun dato

4.0yrs

Durata media

47yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 2487 sono considerati esperti (durata media dell'incarico 4 anni).

Cutia Therapeutics Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Cutia Therapeutics, Annual General Meeting, Jun 05, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Cutia Therapeutics to Report First Half, 2024 Results on Aug 29, 2024

Now 45% undervalued after recent price drop

Cutia Therapeutics Announces Drug Marketing Authorization Application for CU-30101 (Localized Topical Lidocaine and Tetracaine Cream) Accepted by the National Medical Products Administration

New minor risk - Share price stability

Cutia Therapeutics Announces Results of Phase III Clinical Trial of Cu-10201 (Topical 4% Minocycline Foam) in the PRC Published Online in the Journal of the European Academy of Dermatology and Venereology

Cutia Therapeutics (SEHK:2487) commences an Equity Buyback for 30,473,862 shares, representing 10% of its issued share capital, under the authorization approved on June 5, 2024.

Cutia Therapeutics (SEHK:2487) commences an Equity Buyback for 30,473,862 shares, representing 10% of its issued share capital, under the authorization approved on June 5, 2024.

Now 43% undervalued after recent price drop

Cutia Therapeutics Announces Last Patient Enrollment in the Phase II Clinical Trial of Cu-20401

Now 23% undervalued after recent price drop

A Look At The Intrinsic Value Of Cutia Therapeutics (HKG:2487)

Cutia Therapeutics Announces Investigational New Drug Application of CU-10101 for Atopic Dermatitis Approved by the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China

Cutia Therapeutics Submits New Drug Application for Cu-40102 (Topical Finasteride Spray) in Hong Kong, PRC

Cutia Therapeutics, Annual General Meeting, Jun 05, 2024

Analysts Are Betting On Cutia Therapeutics (HKG:2487) With A Big Upgrade This Week

Consensus revenue estimates increase by 40%, EPS downgraded

No longer forecast to breakeven

New minor risk - Profitability

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Cutia Therapeutics Announces the Investigational New Drug Application of CU-10101 (Topical Novel Small Molecule Agent) for the Treatment of Mild to Moderate Atopic Dermatitis Accepted by the Center for Drug Evaluation of the National Medical Products Administration

Cutia Therapeutics to Report Fiscal Year 2023 Results on Mar 27, 2024

Consensus revenue estimates increase by 21%

Cutia Therapeutics Announces Completion of Phase I Clinical Trial of CU-20401

Less than half of directors are independent

Cutia Therapeutics Announces New Drug Application for CU-40102 (Topical Finasteride Spray) Accepted by the National Medical Products Administration

Forecast to breakeven in 2026

Cutia Therapeutics Announces Results of Phase III Clinical Trials of CU-40102 (Topical Finasteride Spray) and CU-10201 (Topical 4% Minocycline Foam) in the People's Republic of China

Cutia Therapeutics Announces Phase I Clinical Trial of Cu-20401 Abdominal Adipose Accumulation Completes Database Lock

Cutia Therapeutics Announces Phase I Clinical Trial of Cu-20401 Abdominal Adipose Accumulation Completes Database Lock

Cutia Therapeutics Announces Phase I Clinical Trial of CU-40101 (Topical Small Molecule Thyroid Hormone Receptor Agonist Liniment) in China Reached Primary Endpoint

Cutia Therapeutics Announces All Enrolled Patients Completes Phase I Clinical Trial of CU-20401

Cutia Therapeutics Announces New Drug Application for CU-10201 (Topical 4% Minocycline Foam) Accepted by the National Medical Products Administration

First half 2023 earnings released

New minor risk - Profitability

Cutia Therapeutics Announces Registrational Phase III Clinical Trial of the Group's CU-40102 Conducted in China for the Treatment of Androgenetic Alopecia Reached Primary Endpoint

Cutia Therapeutics Announces Phase I Clinical Trial of CU-40101 (Topical Small Molecule Thyroid Hormone Receptor Agonist Liniment) Completed Database Lock

Cutia Therapeutics Completes Phase Iii Clinical Trial of Cu-30101

Cutia Therapeutics to Report First Half, 2023 Results on Aug 29, 2023

Cutia Therapeutics Announces CU-10201 (Topical 4% Minocycline Foam) Granted Priority Review Designation by the Center for Drug Evaluation of the National Medical Products Administration

Less than half of directors are independent

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media